多發性骨髓瘤病人施行造血幹細胞移植之醫療資源耗用分析

Analysis of Medical Resource Consumption in Multiple Myeloma Patients Who Received Autologous Hematopoietic Stem Cell Transplantation

目的:探討多發性骨髓瘤病人施行造血幹細胞移植之醫療資源耗用分析。

方法:本研究為回溯性之研究,研究樣本取自單一醫學中心,2010 年至 2017 年為 新診斷多發性骨髓瘤且有進行造血幹細胞移植的病人。結果:結果顯示接受造血幹細胞移植的病人年齡為 57.77 ± 8.24 歲,平均門診次數為 97.77 ± 64.72 次,住院次數為 5 ± 3.09 次,急診次數為 3.04 ± 5.02 次, 門診總花費為 1,318,724.23 ± 1,009,450.62 元,住院總花費為 1,020,685.5 ±478,821.88 元。

結論:接受治療的病人在第一年的門診及住院費用為最高,第二年之後會開始遞 減,而不接受治療的人則有相反的表現,第一年門診及住院費用最低,之後開始逐年上升,所花的醫療費用比接受治療的人更高。

 

Objectives: We conducted a medical resource consumption analysis in multiple myeloma patients who received hematopoietic stem cell transplantation at a single center.
Methods: This was a retrospective study, and the subjects were newly diagnosed multiple myeloma patients who received hematopoietic stem cell transplantation from January 2010 to 31 December 2017 at a single medical center.

Results: The mean age of patients who received hematopoietic stem cell transplantation was 57.77 ± 8.24 years. The mean number of outpatient visits was 97.77 ± 64.72, mean number of hospitalizations was 5 ± 3.09, mean number of emergency department visits was 3.04 ± 5.02, total outpatient cost was 1,318,724.23 ± 1,009,450.62 NTD, and total hospitalization cost was 1,020,685.5 ± 478,821.88 NTD.

Conclusions: This study showed that the cost was the highest during the period of active treatment, and if the patient’s condition improved, the cost would decrease accordingly. This result was similar to that of our study, in which the outpa-tient and hospitalization expenses of the treated patients were the highest in the first year and began to decrease after the second year. The opposite was true for untreated patients whose outpatient and hospitalization expenses were the lowest in the first year and then increased annually. The medical expenses of untreated patients were higher than those of treated patients.